National Research (NASDAQ:NRC) Rating Lowered to Hold at Wall Street Zen

National Research (NASDAQ:NRC) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

NRC has been the topic of several other research reports. Citizens Jmp boosted their price target on shares of National Research from $23.00 to $26.00 and gave the company a “market outperform” rating in a research report on Wednesday, July 29th. Weiss Ratings downgraded shares of National Research from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $26.00.

National Research Price Performance

NRC opened at $21.19 on Friday. National Research has a twelve month low of $11.01 and a twelve month high of $23.68. The company’s 50-day moving average price is $20.63 and its two-hundred day moving average price is $18.23. The stock has a market cap of $482.07 million, a price-to-earnings ratio of 84.76 and a beta of 0.34. The company has a quick ratio of 0.65, a current ratio of 0.65 and a debt-to-equity ratio of 13.13.

National Research (NASDAQ:NRC) last posted its quarterly earnings results on Tuesday, July 28th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.46. National Research had a net margin of 4.18% and a return on equity of 164.26%. The company had revenue of $35.39 million for the quarter, compared to analysts’ expectations of $34.90 million.

Institutional Trading of National Research

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. M&T Bank Corp boosted its position in shares of National Research by 6.4% during the second quarter. M&T Bank Corp now owns 13,608 shares of the company’s stock valued at $229,000 after buying an additional 823 shares during the last quarter. Sei Investments Co. boosted its holdings in shares of National Research by 1.2% during the 3rd quarter. Sei Investments Co. now owns 76,270 shares of the company’s stock valued at $975,000 after acquiring an additional 900 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of National Research by 85.6% in the third quarter. Russell Investments Group Ltd. now owns 1,997 shares of the company’s stock worth $26,000 after acquiring an additional 921 shares during the period. Invesco Ltd. raised its holdings in shares of National Research by 6.3% during the second quarter. Invesco Ltd. now owns 17,368 shares of the company’s stock valued at $292,000 after purchasing an additional 1,022 shares during the last quarter. Finally, Alliancebernstein L.P. raised its holdings in shares of National Research by 6.3% during the third quarter. Alliancebernstein L.P. now owns 18,499 shares of the company’s stock valued at $236,000 after purchasing an additional 1,100 shares during the last quarter. Institutional investors own 47.26% of the company’s stock.

National Research Company Profile

National Research Corp (NASDAQ: NRC), also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company’s cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.